[Morphologic study of iliac crest spongiosa in patients with osteoporosis treated according to the ADFR (activation, depression of resorption, formation, repeat the cycle) with parathyroid hormone and diphosphonates (Hannover PTH I study)].
Treatment of osteoporosis with a complete reconstruction of the normal three dimensional architecture of trabecular bone is an unsolved problem. In addition to the well established fluoride therapy new concepts in the treatment of osteoporosis were developed. There is growing interest in the so called ADFR concept (activation, depression of resorption, formation, repeat the cycle) as a physiological stimulation of osteoblastic bone formation. The histological results following ADFR treatment in 8 patients are reported. After 12 months of treatment with parathyroid hormone [1-38)hPTH) (stimulation of the basic metabolic units) and the diphosphonate EHDP (depression of osteoclastic resorption) no change of remodelling processes at the trabecular bone surface could be observed. The results demonstrate many doubts in the importance of the ADFR concept for the treatment of osteoporosis.
Delling
G
G
Abt. Osteopathologie, Institut für Pathologie der Universität Hamburg.
Dreyer
T
T
Hahn
M
M
Vogel
M
M
Rittinghaus
E F
EF
Hesch
R D
RD
D000328:Adult; D001706:Biopsy; D001842:Bone and Bones / Q000187:drug effects*; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007085:Ilium / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010010:Osteoclasts / Q000187:drug effects*; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000473:pathology; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000627:therapeutic use*
D010281:Parathyroid Hormone; D010446:Peptide Fragments; C035747:parathyroid hormone (1-38); D012968:Etidronic Acid
Morphologische Untersuchung der Beckenkammspongiosa bei Patienten mit Osteoporose unter Therapie nach dem ADFR-Konzept mit Parathormon und Diphosphonaten (PTH I-Studie Hannover).